Multiple ascending dose study of extended-release oral formulation of EV-077.
Phase of Trial: Phase I
Latest Information Update: 15 Jul 2011
At a glance
- Drugs SER 150 (Primary)
- Indications Cardiovascular disorders; Thrombosis
- Focus Adverse reactions
- 15 Jul 2011 Status changed from recruiting to completed, according to information in an Evolva media release.
- 16 Dec 2010 New trial record
- 16 Dec 2010 This study is expected to be completed in the first half of 2011, according to an Evolva media release.